Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{5631cdba82c64f719c991dd1058db421,
title = "Response to Biologics During the First Six Months of Therapy in Biologic-na{\"i}ve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study",
abstract = "Early response to treatment with biologics might be important for the stability of psoriasis and long-term outcome. The aim of this study was therefore to assess whether risk of flares and drug survival are associated with disease activity in the first 6 months of treatment of psoriasis with biologics. Biologic-na{\"i}ve patients from the Danish nationwide registry, DERMBIO, were grouped based on absolute Psoriasis Area and Severity Index (PASI) during the first 6 months of treatment, as: PASI = 0, PASI > 0-≤2, PASI > 2-≤ 4, and PASI > 4. Among 1,684 patients, 746 achieved PASI= 0, 485 PASI > 0-≤2, 246 PASI > 2-≤4, and 207 PASI > 4. Longer flare-free period and drug survival were observed for patients with lower PASI in the first 6 months of treatment (adjusted hazard ratios for flares (95% confidence interval) with PASI=  0 as reference: PASI > 0-≤2 (1.35 (1.11-1.72]), PASI > 2-≤ 4 (2.32 [1.80-2.99]), and PASI > 4 (2.38 [1.80-3.15])). In conclusion, a low PASI in the first 6 months of treatment with biologics in biologic-na{\"i}ve patients with psoriasis was associated with a more stable disease course, lower risk of flares, and longer drug survival.",
keywords = "Biologics, Drug survival, Flares, PASI90PASI100, Psoriasis",
author = "Nikolai Loft and Alexander Egeberg and Rasmussen, {Mads Kirchheiner} and Bryld, {Lars Erik} and Nissen, {Christoffer V} and Dam, {Tomas Norman} and Ajgeiy, {Kawa Khaled} and Lars Iversen and Lone Skov",
year = "2021",
month = jan,
day = "4",
doi = "10.2340/00015555-3722",
language = "English",
volume = "101",
pages = "1--7",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Forum for Nordic Dermato-Venereology",
number = "1",

}

RIS

TY - JOUR

T1 - Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares

T2 - A Danish Nationwide Study

AU - Loft, Nikolai

AU - Egeberg, Alexander

AU - Rasmussen, Mads Kirchheiner

AU - Bryld, Lars Erik

AU - Nissen, Christoffer V

AU - Dam, Tomas Norman

AU - Ajgeiy, Kawa Khaled

AU - Iversen, Lars

AU - Skov, Lone

PY - 2021/1/4

Y1 - 2021/1/4

N2 - Early response to treatment with biologics might be important for the stability of psoriasis and long-term outcome. The aim of this study was therefore to assess whether risk of flares and drug survival are associated with disease activity in the first 6 months of treatment of psoriasis with biologics. Biologic-naïve patients from the Danish nationwide registry, DERMBIO, were grouped based on absolute Psoriasis Area and Severity Index (PASI) during the first 6 months of treatment, as: PASI = 0, PASI > 0-≤2, PASI > 2-≤ 4, and PASI > 4. Among 1,684 patients, 746 achieved PASI= 0, 485 PASI > 0-≤2, 246 PASI > 2-≤4, and 207 PASI > 4. Longer flare-free period and drug survival were observed for patients with lower PASI in the first 6 months of treatment (adjusted hazard ratios for flares (95% confidence interval) with PASI=  0 as reference: PASI > 0-≤2 (1.35 (1.11-1.72]), PASI > 2-≤ 4 (2.32 [1.80-2.99]), and PASI > 4 (2.38 [1.80-3.15])). In conclusion, a low PASI in the first 6 months of treatment with biologics in biologic-naïve patients with psoriasis was associated with a more stable disease course, lower risk of flares, and longer drug survival.

AB - Early response to treatment with biologics might be important for the stability of psoriasis and long-term outcome. The aim of this study was therefore to assess whether risk of flares and drug survival are associated with disease activity in the first 6 months of treatment of psoriasis with biologics. Biologic-naïve patients from the Danish nationwide registry, DERMBIO, were grouped based on absolute Psoriasis Area and Severity Index (PASI) during the first 6 months of treatment, as: PASI = 0, PASI > 0-≤2, PASI > 2-≤ 4, and PASI > 4. Among 1,684 patients, 746 achieved PASI= 0, 485 PASI > 0-≤2, 246 PASI > 2-≤4, and 207 PASI > 4. Longer flare-free period and drug survival were observed for patients with lower PASI in the first 6 months of treatment (adjusted hazard ratios for flares (95% confidence interval) with PASI=  0 as reference: PASI > 0-≤2 (1.35 (1.11-1.72]), PASI > 2-≤ 4 (2.32 [1.80-2.99]), and PASI > 4 (2.38 [1.80-3.15])). In conclusion, a low PASI in the first 6 months of treatment with biologics in biologic-naïve patients with psoriasis was associated with a more stable disease course, lower risk of flares, and longer drug survival.

KW - Biologics

KW - Drug survival

KW - Flares

KW - PASI90PASI100

KW - Psoriasis

UR - http://www.scopus.com/inward/record.url?scp=85099326675&partnerID=8YFLogxK

U2 - 10.2340/00015555-3722

DO - 10.2340/00015555-3722

M3 - Journal article

C2 - 33320277

VL - 101

SP - 1

EP - 7

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 1

M1 - adv00357

ER -

ID: 61760793